Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 841 AL 855

p38α Mitogen-Activated Protein Kinase-An Emerging Drug Target for the Treatment of Alzheimer's Disease

Detka J, Płachtij N, Strzelec M, Manik A, Sałat K.

Molecules. 2024 Sep 13;29(18):4354. doi: 10.3390/molecules29184354.

Naringin and Naringenin: Potential Multi-Target Agents for Alzheimer's Disease

Lu J, Chen J, Li SY, Pan GJ, Ou Y, Yuan LF, Jiang JP, Zeng LH, Zhao J.

Curr Med Sci. 2024 Oct;44(5):867-882. doi: 10.1007/s11596-024-2921-z. Epub 2024 Sep 30.

Progress in the Treatment of Alzheimer's Disease Is Needed - Position Statement of European Alzheimer's Disease Consortium (EADC) Investigators

Jessen F, Kramberger MG, Angioni D, Aarsland D, Balasa M, Bennys K, Boada M, Boban M, Chincarini A, Exalto L, Felbecker A, Fliessbach K, Frisoni GB, Garza-Martínez AJ, Grimmer T, Hanseeuw B, Hort J, Ivanoiu A, Klöppel S, Krajcovicova L, McGuinness B, Mecocci P, de Mendonca A, Nous A, Ousset PJ, Paquet C, Perneczky R, Peters O, Tabuas-Pereira M, Piazza F, Plantone D, Riverol M, Ruiz A, Sacco G, Santana I, Scarmeas N, Solje E, Stefanova E, Sutovsky S, van der Flier W, Welsh T, Wimo A, Winblad B, Frölich L, Engelborghs S.

J Prev Alzheimers Dis. 2024;11(5):1212-1218. doi: 10.14283/jpad.2024.153.

Semorinemab Pharmacokinetics and The Effect on Plasma Total Tau Pharmacodynamics in Clinical Studies

Ramakrishnan V, Bender B, Langenhorst J, Magnusson MO, Dolton M, Shim J, Fuji RN, Monteiro C, Teng E, Kassir N, Jin J.

J Prev Alzheimers Dis. 2024;11(5):1241-1250. doi: 10.14283/jpad.2024.146.

A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer's disease (AD)

Gehlot P, Pathak R, Kumar S, Choudhary NK, Vyas VK.

Bioorg Med Chem. 2024 Nov 1;113:117925. doi: 10.1016/j.bmc.2024.117925. Epub 2024 Sep 14.

Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial

Koychev I, Reid G, Nguyen M, Mentz RJ, Joyce D, Shah SH, Holman RR.

Alzheimers Res Ther. 2024 Oct 2;16(1):212. doi: 10.1186/s13195-024-01573-x.

Gut microbiota and Alzheimer's disease: Exploring natural product intervention and the Gut-Brain axis for therapeutic strategies

Pasupalak JK, Rajput P, Gupta GL.

Eur J Pharmacol. 2024 Dec 5;984:177022. doi: 10.1016/j.ejphar.2024.177022. Epub 2024 Oct 1.

Orexin Receptor Antagonists for the Prevention and Treatment of Alzheimer's Disease and Associated Sleep Disorders

Carpi M, Mercuri NB, Liguori C.

Drugs. 2024 Nov;84(11):1365-1378. doi: 10.1007/s40265-024-02096-3. Epub 2024 Oct 4.

β-amyloid's neurotoxic mechanisms as defined by in vitro microelectrode arrays: a review

O'Connell A, Quinlan L, Kwakowsky A.

Pharmacol Res. 2024 Nov;209:107436. doi: 10.1016/j.phrs.2024.107436. Epub 2024 Oct 4.

Free radicals in Alzheimer's disease: From pathophysiology to clinical trial results

Viña J, Borrás C, Mas-Bargues C.

Free Radic Biol Med. 2024 Nov 20;225:296-301. doi: 10.1016/j.freeradbiomed.2024.09.051. Epub 2024 Oct 5.

Recent Advances in Medicinal Chemistry of Memantine Against Alzheimer's Disease

Singh YP, Kumar H.

Chem Biol Drug Des. 2024 Oct;104(4):e14638. doi: 10.1111/cbdd.14638.

The Basis of Anti-Aβ Antibody Therapy: The Toxicity of Aβ Aggregates and the Mechanism of Action of Anti-Aβ Antibodies

Ono K, Noguchi-Shinohara M, Watanabe-Nakayama T.

Intern Med. 2026 Jan 1;65(1):41-45. doi: 10.2169/internalmedicine.4569-24. Epub 2024 Oct 4.

[Anti-Amyloid Antibody Therapy for Alzheimer's Disease]

Shinohara M, Ono K.

Brain Nerve. 2024 Oct;76(10):1119-1125. doi: 10.11477/mf.1416202747.

Sex- and dose-dependent catalase increase and its clinical impact in a benzoate dose-finding, randomized, double-blind, placebo-controlled trial for Alzheimer's disease

Lane HY, Wang SH, Lin CH.

Pharmacol Biochem Behav. 2024 Dec;245:173885. doi: 10.1016/j.pbb.2024.173885. Epub 2024 Oct 9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias